Chen Iris, Khaki Leila, Lindsey Jane C, Fry Carrie, Cousins Matthew M, Siliciano Robert F, Violari Avy, Palumbo Paul, Eshleman Susan H
Dept. of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
PLoS One. 2013 Nov 27;8(11):e81213. doi: 10.1371/journal.pone.0081213. eCollection 2013.
In HIV-infected children, viral diversity tends to increase with age in the absence of antiretroviral treatment (ART). We measured HIV diversity in African children (ages 6-36 months) enrolled in a randomized clinical trial comparing two ART regimens (Cohort I of the P1060 trial). Children in this cohort were exposed to single dose nevirapine (sdNVP) at birth.
HIV diversity was measured retrospectively using a high resolution melting (HRM) diversity assay. Samples were obtained from 139 children at the enrollment visit prior to ART initiation. Six regions of the HIV genome were analyzed: two in gag, one in pol, and three in env. A single numeric HRM score that reflects HIV diversity was generated for each region; composite HRM scores were also calculated (mean and median for all six regions).
In multivariable median regression models using backwards selection that started with demographic and clinical variables, older age was associated with higher HRM scores (higher HIV diversity) in pol (P = 0.005) and with higher mean (P = 0.014) and median (P<0.001) HRM scores. In multivariable models adjusted for age, pre-treatment HIV viral load, pre-treatment CD4%, and randomized treatment regimen, higher HRM scores in pol were associated with shorter time to virologic suppression (P = 0.016) and longer time to study endpoints (virologic failure [VF], VF/death, and VF/off study treatment; P<0.001 for all measures).
In this cohort of sdNVP-exposed, ART-naïve African children, higher levels of HIV diversity in the HIV pol region prior to ART initiation were associated with better treatment outcomes.
在未接受抗逆转录病毒治疗(ART)的HIV感染儿童中,病毒多样性往往随年龄增长而增加。我们在一项比较两种ART方案的随机临床试验(P1060试验队列I)中,测量了非洲6至36个月大儿童的HIV多样性。该队列中的儿童在出生时接受了单剂量奈韦拉平(sdNVP)。
使用高分辨率熔解(HRM)多样性分析方法对HIV多样性进行回顾性测量。在开始ART之前的入组访视时,从139名儿童中获取样本。分析了HIV基因组的六个区域:gag中的两个区域、pol中的一个区域和env中的三个区域。为每个区域生成一个反映HIV多样性的单一数字HRM分数;还计算了综合HRM分数(所有六个区域的平均值和中位数)。
在使用向后选择的多变量中位数回归模型中,以人口统计学和临床变量开始,年龄较大与pol区域中较高的HRM分数(较高的HIV多样性)相关(P = 0.005),与较高的平均HRM分数(P = 0.014)和中位数HRM分数(P<0.001)相关。在针对年龄、治疗前HIV病毒载量、治疗前CD4%和随机治疗方案进行调整的多变量模型中,pol区域中较高的HRM分数与病毒学抑制时间较短相关(P = 0.016),与研究终点时间较长相关(病毒学失败[VF]、VF/死亡和VF/停止研究治疗;所有测量指标P<0.001)。
在这个暴露于sdNVP、未接受过ART的非洲儿童队列中,ART开始前HIV pol区域中较高水平的HIV多样性与更好的治疗结果相关。